Taken together, our findings usher a potential new therapeutic approach to T1D immunotherapy which involves suppresisve B-cells, possibly homogeneous Bregs, together with approaches and molecules that stabilise their suppressive ability and expand their numbers in vitro (e.g. RA, IL-10, IL-21 [86]). Here, IL21 is linked to type 1 diabetes mellitus.